ACTH (1-17) TFA, an adrenocorticotropin analogue, is a potent human melanocortin 1 (MC1) receptor agonist with a Ki of 0.21 nM.
ACTH (1-17) TFA, also known as Adrenocorticotropic Hormone (1-17) trifluoroacetate salt, is a synthetic peptide fragment corresponding to the N-terminal amino acid residues 1 through 17 of the full-length ACTH polypeptide. As a bioactive peptide, it retains significant portions of the functional domains responsible for receptor binding and partial biological activity, making it an important research tool for dissecting the structure-activity relationships of melanocortin peptides. Its defined sequence and chemical stability in trifluoroacetate form enable precise experimental manipulation, supporting a wide range of investigations into peptide-mediated signaling, neuroendocrine pathways, and receptor pharmacology.
Peptide structure-function analysis: Researchers utilize ACTH (1-17) TFA to elucidate the minimal sequence requirements necessary for activation of melanocortin receptors, particularly MC2R and related subtypes. By comparing the activity of this N-terminal fragment to longer or modified ACTH peptides, scientists can map critical residues responsible for receptor binding, signal transduction, and downstream biological responses. Such studies are fundamental for understanding peptide-receptor interactions and for guiding the rational design of peptide analogs with tailored functional profiles.
Receptor pharmacology and ligand screening: In pharmacological assays, the 1-17 fragment serves as a reference ligand or competitive inhibitor to study the binding affinity and selectivity of melanocortin receptors. Its use in receptor activation or inhibition assays provides insights into ligand-receptor dynamics, aiding in the identification of novel agonists, antagonists, or modulators within the melanocortin system. This is particularly valuable in efforts to characterize receptor subtypes and to delineate the pharmacological landscape of peptide hormones.
Peptide synthesis and analytical method development: The well-defined sequence and physicochemical properties of ACTH (1-17) TFA make it an ideal standard for optimizing solid-phase peptide synthesis protocols and for calibrating analytical techniques such as HPLC, mass spectrometry, and capillary electrophoresis. Its application as a reference peptide supports method validation, quality control, and the development of robust analytical approaches for peptide-based research and manufacturing workflows.
Signal transduction and intracellular pathway studies: The N-terminal fragment is frequently employed in cell-based assays to probe the activation of intracellular signaling cascades initiated by melanocortin receptor engagement. By monitoring second messenger systems, such as cAMP production or kinase activation, in response to peptide stimulation, researchers can dissect the molecular mechanisms underlying peptide hormone action and receptor-mediated communication within neuroendocrine and immune cells.
Neuroendocrine research and peptide mapping: ACTH (1-17) TFA is used as a molecular probe to investigate the biosynthesis, processing, and functional roles of endogenous ACTH fragments in neuroendocrine tissues. Its application in immunoassays, tissue binding studies, and peptide mapping experiments advances the understanding of proopiomelanocortin (POMC) processing pathways and the physiological relevance of truncated ACTH derivatives in the regulation of adrenal function and stress response mechanisms.
2. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
3. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More